Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2017-09-14
Target enrollment:
Participant gender:
Summary
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as
monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics
of patients with type 2 diabetes mellitus starting Trazenta® Tablets or any other oral
antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic
drug).